Table 2.
Regimen | DLL3‐positive (n = 12) | DLL3‐negative (n = 11) |
---|---|---|
CDDP‐CPT‐11 | 8 | 5 |
CDDP + VP16 | 3 | 2 |
CDDP + VNR | 0 | 1 |
CBDCA + VP16 | 0 | 1 |
CBDCA + PTX | 1 | 2 |
CBDCA, carboplatin; CDDP, cisplatin; CPT‐11, irinotecan; PTX, paclitaxel; VP16, etoposide; VNR, vinorelbine.